[October 21, 2016] |
|
T1D Exchange and M2D2 Announce the Winners of the First Annual Diabetes Innovation Challenge
T1D
Exchange, an organization dedicated to accelerating research and
improving outcomes in type 1 diabetes, and M2D2,
a joint venture of the University of Massachusetts Lowell and Worcester
campuses that incubates medical device start-ups, named Integrated
Medical and Enable Biosciences as the co-winners of the new Diabetes
Innovation Challenge. The competition is the first-ever, open,
worldwide challenge to identify and accelerate transformational
advancements in diabetes research and care.
This Smart News Release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20161021005507/en/
The early-to-preclinical stage winner is Integrated Medical of Irvine,
California. The company which is developing a fully-integrated, low
cost, implantable, wireless, continuous glucose monitoring platform.
The late-stage winner (pre-clinical through translational) is Enable
Biosciences. Based in San Francisco, the biotech company is developing
ultrasensitive antibody detection technologies for clinical diagnostics
and research.
"It is essential we do all that we can to support and inspire those who
are working to develop groundbreaking aproaches to find, foster and
facilitate the next generation of impactful solutions for the millions
living with type 1 and type 2 diabetes," said Dana Ball, executive
director and co-founder of T1D Exchange. "Providing the resources to
support, invest, and mentor these exciting ideas and products allows
them to develop into real, impactful solutions and innovations for those
living with diabetes."
The co-winners will share up to $150,000 cash and in-kind services
provided by T1D Exchange and M2D2, and a number of sponsors, including
lead sponsors the American Diabetes Association (Association) and JDRF.
"We were really interested in identifying new, young companies that are
innovating to bring treatments and solutions for people with type 1
diabetes," said Aaron Kowalski, chief mission officer of JDRF. "This has
been a great opportunity to see what's out in the startup landscape, and
we are excited to see what's to come from the winners."
"Getting bright, young minds from fields outside of endocrinology is
critical for moving the needle to improve outcomes for people with
diabetes," said Robert E. Ratner, MD, chief scientific and medical
officer of American Diabetes Association. "The Association is thrilled
to have been a part of the Diabetes Innovation Challenge with T1D
Exchange and M2D2. It has been a successful program to stimulate
creativity and unique approaches to revolutionize how we care for people
with diabetes moving forward."
About T1D Exchange T1D
Exchange, a program of Unitio, was founded on the belief that
improving outcomes in type 1 diabetes (T1D) requires a new approach-one
that helps researchers conduct better research faster; better research
because it's patient-driven and more informed; faster research because
T1D Exchange provides researchers with access to resources they need to
conduct clinical studies. Our innovative model offers researchers access
to aggregated clinical, biological, patient-reported outcomes and
electronic health record data, all while fostering collaboration among
patients, physicians, researchers and industry. Our model is
multi-faceted and complex, but our goal is simple: to tangibly improve
outcomes for people with type 1 diabetes as fast as humanly possible.
About M2D2 M2D2,
the Massachusetts Medical Device Development Center, is a joint
initiative of the Lowell and Worcester campuses of the UMass system. Its
aim is to help new biotech and medical device entrepreneurs develop
products every step of the way, from proof-of-concept to
commercialization. Affiliated faculty and staff have assisted more than
100 start-up companies and entrepreneurs since the program kicked off in
the spring of 2007.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161021005507/en/
[ Back To Mobile World Congress's Homepage ]
|